Metoprolol tartrate

FAQ Print

Metoprolol tartrate

by Wikikenko.com

|

Last updated on


  • Chemical Name: (±)-1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol succinate (2:1) salt
  • Generic Name: Metoprolol succinate
  • Chemical Class: Beta1-selective adrenergic receptor blocker; beta-blocker (antianginal, antihypertensive, and antiarrhythmic class)
  • Formulations: Extended-release oral tablets, typically 25 mg, 50 mg, 100 mg, and 200 mg
  • Brand Names: Toprol-XL, Betaloc, Selokeen, Lopressor (metoprolol brand family), Apo-Metoprolol
  • Manufacturer: AstraZeneca, Teva Pharmaceutical Industries, Sandoz, Mylan/Viatris, Sun Pharmaceutical Industries
  • Regulatory Status: FDA-approved prescription medicine; metoprolol succinate extended-release tablets received initial U.S. approval in 1992
  • Origin: Discovered in 1969, in Sweden
Metoprolol tartrate

Metoprolol tartrate is an immediate-release salt form of metoprolol, a beta-adrenergic receptor blocker used extensively in the management of cardiovascular disease. It is a selective beta1-blocking agent that lowers heart rate, myocardial contractility, and blood pressure by reducing the effects of catecholamines on the heart. The tartrate formulation is designed for rapid absorption and is commonly used when prompt beta-blockade is needed, including in selected patients with acute myocardial infarction and certain arrhythmias.

Metoprolol tartrate differs from metoprolol succinate primarily in its release profile and dosing frequency. Metoprolol tartrate is generally administered two to four times daily, while metoprolol succinate is an extended-release product that is usually taken once daily. Despite these formulation differences, both products deliver the same active pharmacological molecule, metoprolol, and therefore share many therapeutic effects, adverse effects, and safety considerations.

Metoprolol tartrate is available as oral tablets and as an injectable formulation for supervised hospital use. Oral tablets are commonly available in 25 mg, 50 mg, and 100 mg strengths, while the injectable form is reserved for clinical settings where immediate intravenous administration is appropriate.

Chemical Structure

Metoprolol tartrate is the tartrate salt of metoprolol, a synthetic aryloxypropanolamine compound. Its active component, metoprolol, is a beta1-selective adrenergic receptor antagonist. The tartrate salt improves the formulation’s handling and dissolution characteristics, allowing the drug to be absorbed relatively quickly after oral administration.

The pharmacological activity of metoprolol comes from its ability to compete with endogenous catecholamines, such as adrenaline and noradrenaline, for binding to beta-adrenergic receptors. At usual therapeutic concentrations, metoprolol has greater affinity for beta1 receptors, which are abundant in cardiac tissue, than for beta2 receptors, which are more prominent in bronchial and vascular smooth muscle. However, this selectivity is not absolute, particularly at higher plasma concentrations.

Metoprolol tartrate

Metoprolol-Based Medicines List

Metoprolol is available in several salts, formulations, and branded products. The following list includes eight well-known metoprolol-based medicines:

  1. Lopressor — immediate-release metoprolol tartrate tablets.
  2. Metoprolol tartrate tablets — generic immediate-release oral formulation.
  3. Metoprolol tartrate injection — intravenous formulation used in supervised acute-care settings.
  4. Toprol-XL — extended-release metoprolol succinate tablets.
  5. Metoprolol succinate extended-release tablets — generic once-daily formulation.
  6. Betaloc — metoprolol-based beta-blocker brand available in several international markets.
  7. Selokeen — metoprolol-based medicine marketed in parts of Europe.
  8. Metoprolol tartrate and hydrochlorothiazide combination products — combination therapy used for hypertension in certain markets.

The exact product names and availability vary by country. In the United States, metoprolol tartrate tablets are approved for hypertension and for reducing cardiovascular mortality in hemodynamically stable patients with definite or suspected acute myocardial infarction.

Mechanism of Action

Metoprolol tartrate acts primarily by blocking beta1-adrenergic receptors in the heart. Under physical stress, emotional stress, illness, or exercise, the sympathetic nervous system releases catecholamines that increase heart rate, myocardial contractility, and blood pressure. By competitively blocking beta1 receptors, metoprolol reduces these catecholamine-mediated effects.

This blockade lowers resting and exercise heart rate, decreases the velocity and extent of myocardial contraction, and reduces blood pressure. In patients with angina, these changes reduce myocardial oxygen demand, helping to relieve ischemic symptoms and improve exercise tolerance. The FDA label explains that metoprolol reduces catecholamine-induced increases in heart rate, myocardial contraction, and blood pressure, thereby lowering the heart’s oxygen requirement at any given level of effort.

Pharmacokinetics

“Metoprolol tartrate” is rapidly absorbed after oral administration. Because it is an immediate-release formulation, it reaches effective concentrations more quickly than extended-release metoprolol succinate. This property makes it useful when rapid onset of beta-blockade is desired, but it also means that patients generally require multiple daily doses to maintain a consistent therapeutic effect.

After absorption, metoprolol undergoes extensive first-pass metabolism in the liver. It is metabolized predominantly by the cytochrome P450 enzyme CYP2D6. Genetic differences in CYP2D6 activity can influence metoprolol exposure, and coadministration of strong CYP2D6 inhibitors can substantially increase metoprolol concentrations. The FDA label notes that quinidine, a potent CYP2D6 inhibitor, can triple the concentration of S-metoprolol and double the elimination half-life when coadministered with immediate-release metoprolol.

Therapeutic Uses

Therapeutic UseClinical Purpose
HypertensionLowers elevated blood pressure and reduces the risk of fatal and nonfatal cardiovascular events, including stroke and myocardial infarction.
Acute myocardial infarctionReduces cardiovascular mortality in hemodynamically stable patients with definite or suspected acute myocardial infarction, when used alone or following intravenous metoprolol therapy.
Angina pectorisReduces myocardial oxygen demand, decreases anginal episodes, and improves exercise tolerance in patients with ischemic heart disease.
TachyarrhythmiasMay be used under specialist supervision to control excessive heart rate in selected supraventricular arrhythmias.
Post-myocardial infarction managementMay be used as part of long-term cardiovascular risk management in appropriate patients, depending on clinical status and treatment guidelines.
Preoperative cardiovascular risk managementMay be considered in selected patients with established cardiovascular disease, but routine initiation immediately before surgery is not appropriate for all patients and requires individualized assessment.

Side Effects

The most common adverse effects of metoprolol tartrate result from excessive beta-blockade. These include fatigue, dizziness, tiredness, bradycardia, hypotension, cold hands and feet, and reduced exercise tolerance. These effects may be more noticeable when treatment is initiated, when the dose is increased, or when metoprolol is combined with other medicines that lower heart rate or blood pressure.

Gastrointestinal symptoms such as nausea, abdominal discomfort, diarrhea, or constipation can occur. Some patients may experience sleep disturbances, vivid dreams, depression, or reduced exercise capacity. Although metoprolol is relatively cardioselective, it can still worsen bronchospasm in susceptible patients, particularly those with asthma or chronic obstructive pulmonary disease, especially at higher doses.

Drug Interactions

Metoprolol tartrate has several clinically important interactions. Strong CYP2D6 inhibitors can raise metoprolol exposure and intensify beta-blocking effects. Medicines in this category include quinidine, fluoxetine, paroxetine, and propafenone. Increased metoprolol levels may lead to excessive bradycardia, hypotension, dizziness, fatigue, or heart block.

Combining metoprolol with other heart-rate-lowering or blood-pressure-lowering drugs requires caution. These include calcium channel blockers such as verapamil and diltiazem, digoxin, amiodarone, clonidine, and other antihypertensive agents. Such combinations can increase the risk of severe bradycardia, atrioventricular block, hypotension, or reduced cardiac output.

Safety Considerations

Metoprolol tartrate is contraindicated in severe bradycardia, second- or third-degree atrioventricular block, cardiogenic shock, systolic blood pressure below 100 mmHg, decompensated heart failure, and sick sinus syndrome unless a permanent pacemaker is in place. Hypersensitivity to metoprolol or any component of the formulation is also a contraindication.

Patients with asthma, chronic obstructive pulmonary disease, diabetes, peripheral arterial disease, or a history of severe allergic reactions require individualized assessment. Beta-blockers may mask some symptoms of hypoglycemia, especially tremor and palpitations, although sweating may remain. In patients with diabetes, metoprolol can therefore complicate recognition of low blood sugar.

Metoprolol tartrate

Regulatory Status

Metoprolol tartrate tablets are approved by the U.S. Food and Drug Administration for the treatment of hypertension and for reducing cardiovascular mortality in hemodynamically stable patients with definite or suspected acute myocardial infarction. The FDA-approved labeling describes the product as a beta-adrenergic blocker and identifies its immediate-release tablet presentation for oral use.

Metoprolol tartrate is available both as the branded product Lopressor and as generic immediate-release metoprolol tartrate. Regulatory approval, available strengths, and prescribing restrictions differ among countries, so patients should rely on the labeling and prescribing information applicable in their own region.

Conclusion

Metoprolol tartrate is an important immediate-release beta-blocker with established roles in hypertension, stable angina, and selected patients with acute myocardial infarction. Its beta1-selective mechanism lowers heart rate, myocardial oxygen demand, and blood pressure, while its rapid absorption makes it useful when prompt beta-blockade is needed. Although generally effective and widely used, it requires careful attention to heart rate, blood pressure, drug interactions, respiratory disease, diabetes, and the risk associated with abrupt discontinuation. Appropriate use under medical supervision allows metoprolol tartrate to provide meaningful cardiovascular protection for many patients.


0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted


You might also like